2014
DOI: 10.21608/zumj.2014.4369
|View full text |Cite
|
Sign up to set email alerts
|

Urinary Se-Cadherin and Plasma Cystatin C as Novel Biomarkers of Diabetic Nephropathy

Abstract: Background and aim : Diabetes is a major cause of chronic kidney disease (CKD). Urine albumin and estimated glomerular filtration rate (eGFR) are the two key markers for chronic kidney disease (CKD). The aim of our work was to explore the possibility of plasma cystatin C and urinary sE.cadherin as useful biomarkers for early detection of diabetic nephropathy (DN). Methods:-A total number of 80 subjects were included and were classified into three main groups. Group I (20) normal subjects with no history of DM,… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

1
0
0

Year Published

2018
2018
2018
2018

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 15 publications
1
0
0
Order By: Relevance
“…In this study, there was no significant difference between four groups of type 2 diabetic patients regarding sex and BMI, which goes in harmony with Aly et al [18] who found no significant difference between type 2 diabetic patients at different stages of diabetic nephropathy regarding BMI. However, Amin et al [14] showed disagreement with our results, as they found significant increase of BMI in macroalbuminuric patients with T2DM than micoalbuminuric and normoalbuminuric patients with T2DM.…”
Section: Discussionsupporting
confidence: 89%
“…In this study, there was no significant difference between four groups of type 2 diabetic patients regarding sex and BMI, which goes in harmony with Aly et al [18] who found no significant difference between type 2 diabetic patients at different stages of diabetic nephropathy regarding BMI. However, Amin et al [14] showed disagreement with our results, as they found significant increase of BMI in macroalbuminuric patients with T2DM than micoalbuminuric and normoalbuminuric patients with T2DM.…”
Section: Discussionsupporting
confidence: 89%